2017
Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature.
Gressel G, Buza N, Pal L. Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature. European Journal Of Gynaecological Oncology 2017, 38: 214-220. PMID: 29953783.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansHyperandrogenismHysterectomyMiddle AgedNeoadjuvant TherapyNeoplasm GradingOvarian NeoplasmsOvariectomyPostmenopauseRetrospective StudiesSalpingectomySertoli-Leydig Cell TumorConceptsSertoli-Leydig cell tumorOvarian Sertoli-Leydig cell tumorPresent patient populationDisease-free survivalSingle institution experienceTertiary care institutionTime of diagnosisOnset of menopauseRisk of recurrenceSeries of casesAdjuvant chemotherapyMedian followPostmenopausal bleedingPostmenopausal patientsMedian ageMedian intervalClinical presentationDefinitive managementPathological findingsRetrospective reviewInstitution experiencePatient populationTreatment modalitiesCell tumorsTumor grade
1998
Malignancy may adversely influence the quality and behaviour of oocytes.
Pal L, Leykin L, Schifren J, Isaacson K, Chang Y, Nikruil N, Chen Z, Toth T. Malignancy may adversely influence the quality and behaviour of oocytes. Human Reproduction 1998, 13: 1837-1840. PMID: 9740435, DOI: 10.1093/humrep/13.7.1837.Peer-Reviewed Original ResearchConceptsMalignant diseaseMalignant disordersAge-matched patientsCell of originTubal infertilityIVF cyclesOvarian stimulationDefinitive treatmentCase seriesCertain malignanciesNeoplastic processPatientsComparable total numberMature oocytesMalignancyFertilization rateDiseasePotential fertilityApparent adverse influenceOocytesPoor qualityDisordersTotal numberAdverse influenceInfertility